AE

Loading...

Biotech Showcase™ 2019: Stem cell approach shows promise in neurodegeneration

1,593 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jan 15, 2019

https://ebdgroup.knect365.com/biotech...
Recent studies have shown that mesenchymal stem cells (MSCs) hold great potential as a cell‐based therapy for a number of neurodegenerative diseases. Speaking at Biotech Showcase 2019, Chaim Lebovitz, President and CEO, Brainstorm Cell Therapeutics, tells Mike Ward how the New York-based biotech is currently enrolling a multi-dose, double-blind, placebo-controlled Phase III study of its MSC therapy, leveraging the company’s NurOwn platform, in 200 rapid-progressing amyotrophic lateral sclerosis patients.

Comments are turned off
When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...